BIO
Bio-Rad Laboratories Inc - Class AHealth Careinsider_universeEverything we've seen
- ?Sep 14, 6:04 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[distribution] The 20-day PV path tells a clear distribution story. The stock peaked at $390.34 on 2026-08-25 on 296K volume and has since traced a persistent down-and-right arc: by 2026-09-10 price had fallen to $368.75 on the heaviest down-day volume in the window (334K), followed by today's (2026-09-11) marginal +0.15% recovery on 345K — the highest volume in the entire 20-day sample — that failed to reclaim any meaningful ground. Critically, the dominant down-leg from Aug 28 through Sep 11 is characterized by expanding volume on red days (207K → 301K → 256K → 334K → 345K), while the brief up-day on Sep 2 ($388.51, 285K) could not hold and was immediately reversed on lighter, then heavier, selling volume. The SIR path has drifted decisively down-and-right, the hallmark of institutional distribution under the cover of price stabilization near the cluster low. Risks: A multi-session reclaim of the $385–$390 zone on volume above 300K would invalidate the distribution read and suggest the selling pressure has been absorbed. Additionally, macro regime shift — e.g., a sharp steepening of the yield curve beyond the current 0.33 T10Y2Y reading — could act as a sector tailwind for Health Care defensives and lift BIO out of the pattern before the distribution fully resolves.
- ?Sep 10, 3:36 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
With only 10 minutes remaining until the forced close, there is minimal time for continuation to develop meaningfully. The -1.97% move is at the lower end of the 2-5% meaningful-flow threshold, so conviction signal is moderate at best. No news catalyst is present to sustain selling pressure into the close. The macro context (elevated 5Y5Y inflation forward rate, 1.6σ above trend) is mildly rate-sensitive headwind for broad equities but is not a strong BIO-specific driver — biotech is not the most rate-sensitive sector. With 10 minutes left, late-session dynamics tend toward mean reversion or stabilization as algorithms and market makers square books. The combination of very short time horizon, no news fuel, and moderate (not extreme) move magnitude pushes the probability below 0.5, favoring a fade or flat close rather than further downside.
- !Sep 10, 3:36 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
With only 10 minutes remaining until the forced close, there is minimal time for continuation to develop meaningfully. The -1.97% move is at the lower end of the 2-5% meaningful-flow threshold, so conviction signal is moderate at best. No news catalyst is present to sustain selling pressure into the close. The macro context (elevated 5Y5Y inflation forward rate, 1.6σ above trend) is mildly rate-sensitive headwind for broad equities but is not a strong BIO-specific driver — biotech is not the most rate-sensitive sector. With 10 minutes left, late-session dynamics tend toward mean reversion or stabilization as algorithms and market makers square books. The combination of very short time horizon, no news fuel, and moderate (not extreme) move magnitude pushes the probability below 0.5, favoring a fade or flat close rather than further downside.
- ?Sep 10, 1:25 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 1.58% today, which is a meaningful but not dramatic intraday move. No headlines are available to explain the move, so we cannot identify a catalyst with further legs. The macro context shows elevated 5-year forward inflation expectations (T5YIFR at 1.6σ above trend), which is a headwind for rate-sensitive and growth-oriented names — BIO as a life sciences company could face modest pressure here, but the effect is diffuse and not sector-specific enough to be a strong directional driver. With 140 minutes remaining there is ample time for continuation, but also ample time for a mean-reversion into the close as institutional desks opportunistically buy the dip on a name with no apparent fundamental deterioration. The move is below the 2% threshold where momentum tends to self-reinforce, and absent volume data or a clear catalyst, the balance of evidence leans slightly toward fade rather than continuation. Probability set just below 0.5 to avoid triggering a position given weak conviction.
- !Sep 10, 1:25 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is down 1.58% today, which is a meaningful but not dramatic intraday move. No headlines are available to explain the move, so we cannot identify a catalyst with further legs. The macro context shows elevated 5-year forward inflation expectations (T5YIFR at 1.6σ above trend), which is a headwind for rate-sensitive and growth-oriented names — BIO as a life sciences company could face modest pressure here, but the effect is diffuse and not sector-specific enough to be a strong directional driver. With 140 minutes remaining there is ample time for continuation, but also ample time for a mean-reversion into the close as institutional desks opportunistically buy the dip on a name with no apparent fundamental deterioration. The move is below the 2% threshold where momentum tends to self-reinforce, and absent volume data or a clear catalyst, the balance of evidence leans slightly toward fade rather than continuation. Probability set just below 0.5 to avoid triggering a position given weak conviction.
- ?Sep 10, 9:51 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 2.03% with 355 minutes remaining — a meaningful move with ample time to develop further. No headlines to attribute the move to, which is neutral per guidance. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend, which is modestly bearish for rate-sensitive sectors broadly, though BIO (Bio-Rad Laboratories) as a life sciences/tools company has moderate rate sensitivity. The move magnitude is at the lower bound of the 2-5% meaningful flow range, suggesting real selling but not extreme conviction. With no news catalyst, no clear reversal signal, and time remaining substantial, the base case is mild continuation of the downward momentum into the close. However, without stronger volume confirmation data or a clearer macro/sector headwind specific to this name, conviction is limited. Assigning baseline continuation probability at 0.5 — the momentum bias tips it just to the continuation side, but this is a borderline read.
- !Sep 10, 9:51 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is down 2.03% with 355 minutes remaining — a meaningful move with ample time to develop further. No headlines to attribute the move to, which is neutral per guidance. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend, which is modestly bearish for rate-sensitive sectors broadly, though BIO (Bio-Rad Laboratories) as a life sciences/tools company has moderate rate sensitivity. The move magnitude is at the lower bound of the 2-5% meaningful flow range, suggesting real selling but not extreme conviction. With no news catalyst, no clear reversal signal, and time remaining substantial, the base case is mild continuation of the downward momentum into the close. However, without stronger volume confirmation data or a clearer macro/sector headwind specific to this name, conviction is limited. Assigning baseline continuation probability at 0.5 — the momentum bias tips it just to the continuation side, but this is a borderline read.
- ?Sep 4, 10:16 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down -1.84% today, a moderate but meaningful intraday move suggesting real selling flow. However, several factors temper continuation confidence: (1) No news catalyst identified, so the move lacks an obvious fundamental driver that would sustain selling into the close. (2) The macro context shows 5Y5Y forward inflation (T5YIFR) elevated at 1.7σ above trend — this is rate-sensitive broadly, and BIO as a life sciences/biotech name is somewhat rate-sensitive, but the signal is ambiguous in direction for this specific ticker. (3) With 330 minutes remaining (essentially the full afternoon session), there is ample time for either continuation or reversal, which is neutral. (4) A -1.84% move sits at the lower end of the 2-5% 'meaningful conviction' range, so momentum signal is present but not strong. (5) Absence of headlines means no catalyst to anchor sellers or attract new selling. Balancing these factors: the move has real flow behind it but lacks the news, macro tailwind, or magnitude to confidently project sustained selling. Sitting at the minimum threshold for a trade signal.
- !Sep 4, 10:16 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is down -1.84% today, a moderate but meaningful intraday move suggesting real selling flow. However, several factors temper continuation confidence: (1) No news catalyst identified, so the move lacks an obvious fundamental driver that would sustain selling into the close. (2) The macro context shows 5Y5Y forward inflation (T5YIFR) elevated at 1.7σ above trend — this is rate-sensitive broadly, and BIO as a life sciences/biotech name is somewhat rate-sensitive, but the signal is ambiguous in direction for this specific ticker. (3) With 330 minutes remaining (essentially the full afternoon session), there is ample time for either continuation or reversal, which is neutral. (4) A -1.84% move sits at the lower end of the 2-5% 'meaningful conviction' range, so momentum signal is present but not strong. (5) Absence of headlines means no catalyst to anchor sellers or attract new selling. Balancing these factors: the move has real flow behind it but lacks the news, macro tailwind, or magnitude to confidently project sustained selling. Sitting at the minimum threshold for a trade signal.
- ?Sep 2, 9:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is up 1.70% today, a moderate but meaningful intraday move suggesting real buying flow. There are no news catalysts to explain or invalidate the move, which is typical — absence of news does not argue against continuation. The macro context shows the 5Y5Y forward inflation rate elevated at 1.7σ above trend, which is modestly negative for rate-sensitive sectors broadly, but life sciences / biotech tools companies like BIO are not the most acutely rate-sensitive names, so this headwind is mild. With 360 minutes remaining (essentially a full session still ahead), there is ample time for the move to extend, which supports taking the trade. The move is below the 2% threshold that would signal strong conviction, so I'm not elevating this to a high-confidence read. No reversal signals are evident from the data provided. Overall, a modest lean toward continuation with bounded downside via the system's stop discipline.
- !Sep 2, 9:45 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is up 1.70% today, a moderate but meaningful intraday move suggesting real buying flow. There are no news catalysts to explain or invalidate the move, which is typical — absence of news does not argue against continuation. The macro context shows the 5Y5Y forward inflation rate elevated at 1.7σ above trend, which is modestly negative for rate-sensitive sectors broadly, but life sciences / biotech tools companies like BIO are not the most acutely rate-sensitive names, so this headwind is mild. With 360 minutes remaining (essentially a full session still ahead), there is ample time for the move to extend, which supports taking the trade. The move is below the 2% threshold that would signal strong conviction, so I'm not elevating this to a high-confidence read. No reversal signals are evident from the data provided. Overall, a modest lean toward continuation with bounded downside via the system's stop discipline.
- ?Aug 25, 3:31 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is up 2.04% today with only 15 minutes remaining until the forced close. The extremely limited time horizon is the dominant factor here — even if momentum is genuine, there is simply insufficient runway for the +3% profit target to be reached from current levels, and late-session mean reversion or profit-taking is common in the final 15 minutes. The macro context shows elevated 5Y5Y inflation expectations (1.8σ above trend), which creates a mildly unfavorable backdrop for rate-sensitive sectors, though BIO as a life sciences company is not the most rate-sensitive name. No news catalyst is present to explain the move, which is neutral per the framework but combined with the very short time window makes continuation less compelling. The move magnitude (2.04%) is meaningful and suggests real flow, but with 15 minutes left and no fresh catalyst, the risk of a fade into the close outweighs the continuation case. Probability set below 0.5 primarily on time constraint — this same setup with 60+ minutes remaining would warrant 0.52-0.55.
- !Aug 25, 3:31 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is up 2.04% today with only 15 minutes remaining until the forced close. The extremely limited time horizon is the dominant factor here — even if momentum is genuine, there is simply insufficient runway for the +3% profit target to be reached from current levels, and late-session mean reversion or profit-taking is common in the final 15 minutes. The macro context shows elevated 5Y5Y inflation expectations (1.8σ above trend), which creates a mildly unfavorable backdrop for rate-sensitive sectors, though BIO as a life sciences company is not the most rate-sensitive name. No news catalyst is present to explain the move, which is neutral per the framework but combined with the very short time window makes continuation less compelling. The move magnitude (2.04%) is meaningful and suggests real flow, but with 15 minutes left and no fresh catalyst, the risk of a fade into the close outweighs the continuation case. Probability set below 0.5 primarily on time constraint — this same setup with 60+ minutes remaining would warrant 0.52-0.55.
- ?Aug 25, 2:00 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is up 2.02% today with no attributable headline, suggesting this is flow-driven rather than news-driven — not a disqualifier per se, but it limits conviction about the catalyst sustaining into the close. The macro backdrop (T5YIFR at 1.8σ above trend) signals elevated inflation expectations, which is modestly headwind for rate-sensitive and growth-oriented names like BIO, a life science/biotech tools company. However, the move magnitude (just over 2%) reflects real buying conviction, and with 105 minutes remaining there is adequate time for continuation. No reversal signals or fade patterns are evident from the data provided. The macro concern is real but not decisive — biotech tools names can be more idiosyncratic than purely rate-sensitive. Balancing moderate momentum, sufficient time remaining, a mild macro headwind, and the absence of a catalyst to sustain buying, this reads as a borderline continuation setup. No strong reason to fade it, but equally no clear evidence of sustained institutional accumulation into the close.
- !Aug 25, 2:00 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is up 2.02% today with no attributable headline, suggesting this is flow-driven rather than news-driven — not a disqualifier per se, but it limits conviction about the catalyst sustaining into the close. The macro backdrop (T5YIFR at 1.8σ above trend) signals elevated inflation expectations, which is modestly headwind for rate-sensitive and growth-oriented names like BIO, a life science/biotech tools company. However, the move magnitude (just over 2%) reflects real buying conviction, and with 105 minutes remaining there is adequate time for continuation. No reversal signals or fade patterns are evident from the data provided. The macro concern is real but not decisive — biotech tools names can be more idiosyncratic than purely rate-sensitive. Balancing moderate momentum, sufficient time remaining, a mild macro headwind, and the absence of a catalyst to sustain buying, this reads as a borderline continuation setup. No strong reason to fade it, but equally no clear evidence of sustained institutional accumulation into the close.
- ?Aug 6, 10:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down ~2.91% intraday with no attributable headline catalyst. The move is meaningful in magnitude and likely reflects real selling flow. However, several factors limit conviction: (1) No news to anchor or sustain the thesis — absence of catalyst means this could be a one-time block liquidation or sector rotation that is largely complete. (2) The macro context (T5YIE at 1.9σ below trend) suggests deflationary pressure, which is generally not acutely negative for biotech/life sciences and doesn't reinforce a sustained down move. (3) 330 minutes remaining is substantial time, which cuts both ways — enough time for continuation but also enough time for mean reversion or buyers to step in at the -3% discount. (4) No volume abnormality data provided to confirm heavy distribution. On balance, the raw momentum signal and the asymmetric risk structure (tight -1.5% stop vs. +3% target) justify a slight lean toward continuation, but confidence is low. Probability set modestly above 0.5 reflecting the momentum bias without strong confirmatory evidence.
- !Aug 6, 10:15 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
BIO is down ~2.91% intraday with no attributable headline catalyst. The move is meaningful in magnitude and likely reflects real selling flow. However, several factors limit conviction: (1) No news to anchor or sustain the thesis — absence of catalyst means this could be a one-time block liquidation or sector rotation that is largely complete. (2) The macro context (T5YIE at 1.9σ below trend) suggests deflationary pressure, which is generally not acutely negative for biotech/life sciences and doesn't reinforce a sustained down move. (3) 330 minutes remaining is substantial time, which cuts both ways — enough time for continuation but also enough time for mean reversion or buyers to step in at the -3% discount. (4) No volume abnormality data provided to confirm heavy distribution. On balance, the raw momentum signal and the asymmetric risk structure (tight -1.5% stop vs. +3% target) justify a slight lean toward continuation, but confidence is low. Probability set modestly above 0.5 reflecting the momentum bias without strong confirmatory evidence.
- ?Jul 31, 11:00 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 2.13% intraday with no attributable headline, suggesting either broad healthcare/biotech sector selling or idiosyncratic institutional flow. The macro context (elevated mortgage rates at 1.9σ above trend) is not directly relevant to biotech, providing neither tailwind nor headwind. With 285 minutes remaining — essentially a full trading session still ahead — there is ample time for the move to continue or reverse. The absence of news is not a disqualifier; this level of move represents real conviction from size players. However, without a clear catalyst or sector-level confirmation, the setup is ordinary momentum rather than high-conviction continuation. No reversal pattern is evident from available data. Assigning a modest continuation probability slightly above 0.5, reflecting the inherent inertia of an established intraday downtrend with time remaining, but lacking the volume confirmation or sector backdrop needed for higher conviction.
- !Jul 31, 11:00 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is down 2.13% intraday with no attributable headline, suggesting either broad healthcare/biotech sector selling or idiosyncratic institutional flow. The macro context (elevated mortgage rates at 1.9σ above trend) is not directly relevant to biotech, providing neither tailwind nor headwind. With 285 minutes remaining — essentially a full trading session still ahead — there is ample time for the move to continue or reverse. The absence of news is not a disqualifier; this level of move represents real conviction from size players. However, without a clear catalyst or sector-level confirmation, the setup is ordinary momentum rather than high-conviction continuation. No reversal pattern is evident from available data. Assigning a modest continuation probability slightly above 0.5, reflecting the inherent inertia of an established intraday downtrend with time remaining, but lacking the volume confirmation or sector backdrop needed for higher conviction.
- ?Jul 28, 9:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is up 3.60% today with no attributable headline, suggesting this is flow-driven — likely institutional repositioning or sector rotation into life sciences/biotech. The move is meaningful in magnitude and represents real conviction. Macro context shows 10Y inflation expectations (T10YIE) running 1.7σ below trend, which is supportive of longer-duration growth assets like biotech, as lower real rate expectations reduce discount rates on future cash flows. With 360 minutes remaining (effectively a full trading day's worth of intraday time — this appears to be early/mid session), there is ample runway for continuation if momentum holds. No reversal signals are evident from the data provided, and absence of news is not a disqualifier. The main uncertainty is the lack of volume confirmation data and no specific catalyst to anchor the move, which keeps the probability in the moderate range rather than the high-conviction tier. Overall, the balance of evidence slightly favors continuation into the close.
- !Jul 28, 9:45 AMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
BIO is up 3.60% today with no attributable headline, suggesting this is flow-driven — likely institutional repositioning or sector rotation into life sciences/biotech. The move is meaningful in magnitude and represents real conviction. Macro context shows 10Y inflation expectations (T10YIE) running 1.7σ below trend, which is supportive of longer-duration growth assets like biotech, as lower real rate expectations reduce discount rates on future cash flows. With 360 minutes remaining (effectively a full trading day's worth of intraday time — this appears to be early/mid session), there is ample runway for continuation if momentum holds. No reversal signals are evident from the data provided, and absence of news is not a disqualifier. The main uncertainty is the lack of volume confirmation data and no specific catalyst to anchor the move, which keeps the probability in the moderate range rather than the high-conviction tier. Overall, the balance of evidence slightly favors continuation into the close.
- ?Jul 10, 6:03 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[distribution] The 20-day PV path tells a distributive story. After a sharp spike-and-fade — the path surged to $300.79 on 2026-06-26 (482K vol) following an enormous 645K down-day on 2026-06-23 — the subsequent path has drifted persistently lower through a sequence of eight down-days between 2026-06-29 and 2026-07-08, with down-day volumes routinely exceeding up-day volumes (e.g. 329K on the -1.83% day of 2026-06-29 vs. 204K on the +1.19% day of 2026-07-01). Today's +4.73% close at $297.28 on only 170K — a volume z-score of -1.27, well below the 20-day ADV of 328K — is the opposite of a confirming cluster break: price recaptured ground on the thinnest volume of the entire lookback window, signaling lack of conviction and potential short-covering rather than genuine demand. Under the SIR framework, a price recovery on sub-average and shrinking volume deepens the distributional read rather than erasing it. Risks: This bearish read would be invalidated by a subsequent session that closes above ~$300 on volume materially above the 328K ADV, suggesting real demand entering the float. Additionally, the macro tailwind from the 1.5σ below-trend 10-year inflation breakeven (2.23% on 2026-07-09) could disproportionately lift long-duration Health Care names and override the technical distribution signal.
- ?Jul 9, 6:04 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[distribution] The SIR path tells a cautionary story. A high-volume surge on 2026-06-23 (645K, the 20-day peak in volume) drove price down to $270.32, followed by a sharp two-day recovery to $300.79 on strong but fading volume (592K → 482K on Jun 25–26). Critically, every session from Jun 29 through Jul 8 was a DOWN day, with closes walking from $300.79 all the way back to $283.86 — the path drifting down-and-right through volume that, while below average, remained persistent on the sell side. Today's Jul 9 bounce (+4.73% to $297.28) is the single most concerning data point under SIR's rules: volume registered only 170K (z-score −1.27, well below the 20-day ADV of 328K), meaning the price recovery is occurring on the lightest volume of the entire 20-day window — a classic sign that demand is thin and the bounce lacks institutional sponsorship. Risks: A decisive reclaim of $300+ on volume materially above the 328K ADV over multiple sessions would invalidate the distributive read and suggest the June cluster break was genuine accumulation. Renewed down-day volume expansion back toward the 400–645K range on closes below $283 would confirm distribution and expose the $270 low as the next key level.
- ?Jul 9, 10:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is up 1.72% today, a modest but real move suggesting some directional flow. With 330 minutes remaining (essentially the full session), there is ample time for continuation. However, the move is below the 2-5% threshold that would signal strong conviction. No news catalyst is present, which is neutral per guidance. The macro context (T10Y2Y at 2.1σ below trend, flat/slightly inverted curve) is mildly unfavorable for risk-on momentum in non-defensive sectors — BIO as a life sciences/diagnostics company sits in a sector that isn't directly penalized by this yield curve reading, but the broader macro backdrop is not supportive of aggressive risk extension. With no catalyst, moderate move size, and a neutral-to-slightly-cautious macro backdrop, this is a borderline read. Defaulting to slight continuation bias given the system's asymmetric risk structure and the rule that borderline reads resolve in favor of the trade.
- !Jul 9, 10:15 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is up 1.72% today, a modest but real move suggesting some directional flow. With 330 minutes remaining (essentially the full session), there is ample time for continuation. However, the move is below the 2-5% threshold that would signal strong conviction. No news catalyst is present, which is neutral per guidance. The macro context (T10Y2Y at 2.1σ below trend, flat/slightly inverted curve) is mildly unfavorable for risk-on momentum in non-defensive sectors — BIO as a life sciences/diagnostics company sits in a sector that isn't directly penalized by this yield curve reading, but the broader macro backdrop is not supportive of aggressive risk extension. With no catalyst, moderate move size, and a neutral-to-slightly-cautious macro backdrop, this is a borderline read. Defaulting to slight continuation bias given the system's asymmetric risk structure and the rule that borderline reads resolve in favor of the trade.
- ?Jul 9, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $2.62 cash available; close=$283.86.
- !Jul 9, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $2.62 cash available; close=$283.86.
- ?Jul 9, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BIO (Bio-Rad Laboratories) is down 11.3% from its 30-day high with no identifiable negative catalyst — no adverse news headlines, no bearish SEC filings, no insider selling, and no unusual put flow. The company is a well-established life sciences tools and diagnostics provider with a historically solid balance sheet, suggesting the drop is more likely macro- or sector-driven than fundamental. The VIX at the 28th percentile indicates a relatively calm market environment, and the 2s10s spread is modestly positive (+0.36pp), not signaling imminent macro stress. However, the 10Y yield at 4.55% is a mild structural headwind for longer-duration health care equities, and the complete absence of confirmation signals (no insider buys, no call flow, no analyst upgrades) keeps conviction limited.
- !Jul 9, 7:01 AMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BIO (Bio-Rad Laboratories) is down 11.3% from its 30-day high with no identifiable negative catalyst — no adverse news headlines, no bearish SEC filings, no insider selling, and no unusual put flow. The company is a well-established life sciences tools and diagnostics provider with a historically solid balance sheet, suggesting the drop is more likely macro- or sector-driven than fundamental. The VIX at the 28th percentile indicates a relatively calm market environment, and the 2s10s spread is modestly positive (+0.36pp), not signaling imminent macro stress. However, the 10Y yield at 4.55% is a mild structural headwind for longer-duration health care equities, and the complete absence of confirmation signals (no insider buys, no call flow, no analyst upgrades) keeps conviction limited.
- ?Jul 8, 6:04 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BIO (Bio-Rad Laboratories) is down 11.3% from its 30-day high with no identifiable negative catalyst — no adverse news headlines, no bearish SEC filings, no insider selling, and no unusual put flow. The company is a well-established life sciences tools and diagnostics provider with a historically solid balance sheet, suggesting the drop is more likely macro- or sector-driven than fundamental. The VIX at the 28th percentile indicates a relatively calm market environment, and the 2s10s spread is modestly positive (+0.36pp), not signaling imminent macro stress. However, the 10Y yield at 4.55% is a mild structural headwind for longer-duration health care equities, and the complete absence of confirmation signals (no insider buys, no call flow, no analyst upgrades) keeps conviction limited.
- !Jul 8, 6:04 PMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BIO (Bio-Rad Laboratories) is down 11.3% from its 30-day high with no identifiable negative catalyst — no adverse news headlines, no bearish SEC filings, no insider selling, and no unusual put flow. The company is a well-established life sciences tools and diagnostics provider with a historically solid balance sheet, suggesting the drop is more likely macro- or sector-driven than fundamental. The VIX at the 28th percentile indicates a relatively calm market environment, and the 2s10s spread is modestly positive (+0.36pp), not signaling imminent macro stress. However, the 10Y yield at 4.55% is a mild structural headwind for longer-duration health care equities, and the complete absence of confirmation signals (no insider buys, no call flow, no analyst upgrades) keeps conviction limited.
- ?Jul 8, 6:03 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $2.62 cash available; close=$283.86.
- ?Jul 8, 10:05 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 1.51% today, which is a meaningful but not outsized move. With 340 minutes remaining there is ample time for continuation, but several factors temper conviction. First, the macro context shows the T10Y2Y spread at 2.0σ below its 24-month trend, indicating a flattening/near-inverted curve environment. BIO (Bio-Rad Laboratories) is a life sciences/diagnostics name — not a bank — so the direct rate-curve headwind is limited, but a risk-off, defensive-rotation macro backdrop can still weigh on mid-cap industrials/life-science instruments. Second, there are no news catalysts to explain today's move, which means it could be broad market sympathy selling or thin-flow drift rather than a fundamental repricing — both of which are more prone to mean reversion into the close. Third, the move at -1.51% is below the 2-5% threshold where momentum tends to self-reinforce through stop-triggers and forced liquidations. The setup does not meet the bar for a clear continuation trade; the probability of further downside continuation sits just below 0.5, favoring no position.
- !Jul 8, 10:05 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is down 1.51% today, which is a meaningful but not outsized move. With 340 minutes remaining there is ample time for continuation, but several factors temper conviction. First, the macro context shows the T10Y2Y spread at 2.0σ below its 24-month trend, indicating a flattening/near-inverted curve environment. BIO (Bio-Rad Laboratories) is a life sciences/diagnostics name — not a bank — so the direct rate-curve headwind is limited, but a risk-off, defensive-rotation macro backdrop can still weigh on mid-cap industrials/life-science instruments. Second, there are no news catalysts to explain today's move, which means it could be broad market sympathy selling or thin-flow drift rather than a fundamental repricing — both of which are more prone to mean reversion into the close. Third, the move at -1.51% is below the 2-5% threshold where momentum tends to self-reinforce through stop-triggers and forced liquidations. The setup does not meet the bar for a clear continuation trade; the probability of further downside continuation sits just below 0.5, favoring no position.
- !Jul 2, 6:03 PMsignal
options_momentum — insufficient_capital
- !Jul 2, 5:45 PMsignal
options_momentum — insufficient_capital
- !Jul 2, 9:17 AMsignal
options_momentum — insufficient_capital
- !Jul 2, 9:05 AMsignal
options_momentum — insufficient_capital
- !Jul 2, 7:04 AMsignal
options_momentum — insufficient_capital
- !Jul 1, 5:46 PMsignal
options_momentum — insufficient_capital
- !Jul 1, 5:32 PMsignal
options_momentum — insufficient_capital
- !Jul 1, 5:17 PMsignal
options_momentum — insufficient_capital
- !Jul 1, 5:03 PMsignal
options_momentum — insufficient_capital
- !Jul 1, 4:47 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 5:46 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 5:31 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 5:16 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 5:04 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 4:46 PMsignal
options_momentum — insufficient_capital
- ?Jun 30, 10:51 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 1.62% today, which is a moderate but not dramatic intraday move. There are no catalysts or headlines to explain the move, which makes it harder to assess conviction behind the selling. The macro context shows 10Y inflation expectations (T10YIE) printing 1.7σ below trend, which is generally supportive of long-duration assets and growth/biotech names — this slightly argues against further downside continuation in BIO. However, the move itself represents real selling flow, and with 294 minutes remaining there is ample time for continuation if the pressure persists. Balancing: (1) the macro backdrop is mildly counter to further selling in a long-duration sensitive biotech name, (2) no news to anchor the sell thesis, (3) the move is real but not outsized enough to strongly imply sustained institutional distribution, and (4) plenty of time remains. Net result is a borderline read — no strong reason to expect fade but no strong continuation signal either. Assigning minimum threshold probability given the slight macro headwind to the downside thesis.
- ?Jun 25, 7:05 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $13.98 cash available; close=$280.05.
- ?Jun 25, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $57.20 cash available; close=$280.05.
- ?Jun 24, 6:06 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $54.66 cash available; close=$280.03.
- ?Jun 24, 6:06 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
There are no recent news headlines or SEC filings to explain the 10.7% decline, which suggests the drop is likely driven by macro or sector rotation forces rather than company-specific deterioration. Bio-Rad Laboratories (BIO) is a well-established life science and diagnostics company with a historically solid balance sheet, and the absence of negative catalysts supports a "sound" classification. However, the macro context — a flattening yield curve (T10Y2Y at 0.4, 2.1σ below trend) — signals risk-off pressure that can weigh broadly on growth-sensitive industrials and life science names, reducing near-term rebound conviction.
- ?Jun 24, 6:06 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $15.05 cash available; close=$280.03.
- ?Jun 24, 7:04 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $4.36 cash available; close=$270.32.
- ✓Jun 24, 7:04 AMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
The 15.5% drop from the 30-day high has no identifiable fundamental catalyst — no negative news headlines, no adverse SEC filings, and no insider selling. The most notable signal is the strongly unusual options flow: call volume z-score of +0.48 vs. an extremely suppressed put volume (z=-2.97), yielding a P/C ratio of just 0.13, suggesting informed market participants are positioned for upside rather than further downside. The Health Care sector (XLV) is showing relative strength with a +2.35pt 5-day outperformance vs. SPY, suggesting the drop is idiosyncratic and potentially overdone rather than sector-driven deterioration.
- ?Jun 23, 8:11 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[distribution] The 20-day PV path traces a clear distribution signature: after peaking at $318.22 on 2026-05-28 on the period's heaviest up-day volume (652K), the path has drifted steadily lower through a series of declining closes, with down-days routinely commanding more volume than up-days. The most damning evidence is the final bar on 2026-06-23: a -3.84% close at $270.32 on 544K shares — the second-highest volume of the entire window and the highest in the recent declining stretch — as the price breaks to a new 20-day low, a textbook down-right vector in 2-D PV space. Meanwhile, the modest up-days in the June 9–16 range (closes $289–$297) were accompanied by volume ranging only 227K–437K, confirming sellers were absorbing any attempted rally with expanding supply. Risks: A reversal on sustained up-day volume materially above the 376K ADV — particularly a session that reclaims the $285–$290 cluster on 500K+ volume — would challenge the distribution read and suggest a potential climax washout bottom. Additionally, the macro backdrop of a 10-year inflation breakeven 1.7σ below trend could benefit Health Care as a long-duration-sensitive sector if rates reprice sharply lower, providing a fundamental tailwind that overrides the bearish PV path.
- ?Jun 23, 8:51 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $19.16 cash available; close=$281.11.
- ?Jun 23, 7:04 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $91.33 cash available; close=$281.11.
- ?Jun 23, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $19.16 cash available; close=$281.11.
- ?Jun 22, 7:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $12.30 cash available; close=$281.11.
- ?Jun 22, 7:21 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
There are no recent news headlines or SEC filings to explain the 10.7% decline, which suggests the drop is likely driven by macro or sector rotation forces rather than company-specific deterioration. Bio-Rad Laboratories (BIO) is a well-established life science and diagnostics company with a historically solid balance sheet, and the absence of negative catalysts supports a "sound" classification. However, the macro context — a flattening yield curve (T10Y2Y at 0.4, 2.1σ below trend) — signals risk-off pressure that can weigh broadly on growth-sensitive industrials and life science names, reducing near-term rebound conviction.
- ?Jun 22, 6:06 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $16.31 cash available; close=$281.11.
- ?Jun 22, 11:16 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down ~1.92% today with 270 minutes remaining, which is a meaningful but not extreme move. There are no recent headlines to explain the drop, so this appears to be flow-driven rather than news-catalyzed. The macro context (5Y inflation expectations 1.5σ below trend) is modestly disinflationary, which is broadly neutral-to-negative for healthcare/biotech names but not a strong directional signal for BIO specifically. With 270 minutes remaining there is ample time for continuation if selling pressure persists, but the move is below the 2-5% threshold where momentum becomes more self-sustaining. No clear reversal signals are evident, but the lack of any identifiable catalyst or sector-specific tailwind keeps conviction moderate. Assigning baseline continuation probability given absence of counter-evidence and time remaining, without strong reason to expect a fade or an acceleration.
- ?Jun 22, 7:05 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $46.35 cash available; close=$282.44.
- ?Jun 22, 7:05 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.92 cash available; close=$282.44.
- ?Jun 18, 6:21 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
There are no recent news headlines or SEC filings to explain the 10.7% decline, which suggests the drop is likely driven by macro or sector rotation forces rather than company-specific deterioration. Bio-Rad Laboratories (BIO) is a well-established life science and diagnostics company with a historically solid balance sheet, and the absence of negative catalysts supports a "sound" classification. However, the macro context — a flattening yield curve (T10Y2Y at 0.4, 2.1σ below trend) — signals risk-off pressure that can weigh broadly on growth-sensitive industrials and life science names, reducing near-term rebound conviction.
- ?Jun 18, 6:05 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $63.15 cash available; close=$282.40.
- ?Jun 18, 6:04 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.52 cash available; close=$282.40.
- ?Jun 18, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $10.13 cash available; close=$284.67.
- ?Jun 18, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $80.33 cash available; close=$284.67.
- ?Jun 17, 6:06 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $11.35 cash available; close=$284.67.
- ?Jun 17, 6:05 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $3.62 cash available; close=$284.67.
- ?Jun 17, 6:05 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
There are no recent news headlines or SEC filings to explain the 10.7% decline, which suggests the drop is likely driven by macro or sector rotation forces rather than company-specific deterioration. Bio-Rad Laboratories (BIO) is a well-established life science and diagnostics company with a historically solid balance sheet, and the absence of negative catalysts supports a "sound" classification. However, the macro context — a flattening yield curve (T10Y2Y at 0.4, 2.1σ below trend) — signals risk-off pressure that can weigh broadly on growth-sensitive industrials and life science names, reducing near-term rebound conviction.
- ?Jun 15, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $8.19 cash available; close=$285.94.
- ?Jun 15, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $7.49 cash available; close=$285.94.
- ?Jun 12, 6:04 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $19.87 cash available; close=$285.69.
- ?Jun 12, 6:04 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $13.51 cash available; close=$285.69.
- ?Jun 12, 6:04 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
There are no recent news headlines or SEC filings to explain the 10.7% decline, which suggests the drop is likely driven by macro or sector rotation forces rather than company-specific deterioration. Bio-Rad Laboratories (BIO) is a well-established life science and diagnostics company with a historically solid balance sheet, and the absence of negative catalysts supports a "sound" classification. However, the macro context — a flattening yield curve (T10Y2Y at 0.4, 2.1σ below trend) — signals risk-off pressure that can weigh broadly on growth-sensitive industrials and life science names, reducing near-term rebound conviction.